全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

Sangramento em síndrome coronariana aguda sem supradesnivelamento de segmento ST Bleeding in non-ST-segment elevation acute coronary syndrome

Valor prognóstico da interleucina-6 na evolu o de pacientes com síndrome coronariana aguda sem supradesnivelamento de segmento ST =Prognostic value of interleukin-6 in the outcome of patients with acute coronary syndrome without ST-segment elevation

Avalia o das press es sistólica, diastólica e press o de pulso como fator de risco para doen a aterosclerótica coronariana grave em mulheres com angina instável ou infarto agudo do miocárdio sem supradesnivelamento do segmento ST

Avalia o tecnológica e análise custo-efetividade em saúde: a incorpora o de tecnologias e a produ o de diretrizes clínicas para o SUS

Indicadores de Efetividade em custo de atividades-meio no modelo de gest o para resultados: a experiência do Ipec/Fiocruz

Cost-effectiveness analysis: comparison of traditional Custo-efetividade: compara o entre o modelo tradicional e o Programa de Saúde da Família.

Compara o da coronariografia de mulheres diabéticas e n o-diabéticas com síndrome coronariana aguda sem supradesnivelamento de ST

Análise de custo-efetividade dos stents farmacológicos e n?o farmacológicos na doen?a coronariana

Custo-efetividade de programa de educa o para adultos asmáticos atendidos em hospital-escola de institui o pública

Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies

更多...

Custo-efetividade de fondaparinux em pacientes com Síndrome Coronariana Aguda sem supradesnivelamento do ST

DOI: 10.1590/S0066-782X2012005000060

Keywords: acute coronary syndrome, anticoagulants [therapeutic use], anticoagulants [adverse effects], enoxaparin [therapeutic use], enoxaparin [adverse effects], cost benefits analysis.

Full-Text   Cite this paper   Add to My Lib

Abstract:

background: the combined use of antithrombotic agents, antiplatelet agents and invasive strategies in acute coronary syndrome without st-segment elevation (acswste) reduces cardiovascular events. fondaparinux has demonstrated equivalence to enoxaparin in reducing cardiovascular events, but with a lower rate of bleeding in patients using fondaparinux. objective: evaluate the cost-effectiveness of fondaparinux versus enoxaparin in patients with acswste in brazil from the economic perspective of the brazilian unified health system (sus). methods: a decision analytic model was constructed to calculate the costs and consequences of the compared treatments. the model parameters were obtained from the oasis-5 study (n = 20,078 patients with acswste randomized to fondaparinux or enoxaparin). the target outcome consisted of cardiovascular events (i.e., death, myocardial infarction, refractory ischemia and major bleeding) on days 9, 30 and 180 after acswste. we evaluated all direct costs of treatment and acswste-related events. the year of the analysis was 2010 and the costs were described in reais (r$). results: on day 9, the cost of treatment per patient was r$ 2,768 for fondaparinux and r$ 2,852 for enoxaparin. approximately 80% of total costs were associated with invasive treatments. the drug costs accounted for 10% of the total cost. the combined rates of cardiovascular events and major bleeding were 7.3% and 9.0% for fondaparinux and enoxaparin, respectively. sensitivity analyses confirmed the initial results of the model. conclusion: the use of fondaparinux for the treatment of patients with acswste is superior to that of enoxaparin in terms of prevention of further cardiovascular events at lower cost. (arq bras cardiol. 2012; [online].ahead print, pp.0-0)

Full-Text

comments powered by Disqus